nAture methods online methods Oligonucleotides and sequences. All oligonucleotides were purchased from Integrated DNA Technologies or Invitrogen and are listed in Supplementary Table 7 . Primers with degenerate positions were synthesized by Integrated DNA Technologies using hand-mixed phosphoramidites containing 79% of the indicated base and 7% of each of the other standard DNA bases.
engineered zinc-finger nucleases (ZFns) are promising tools for genome manipulation, and determining off-target cleavage sites of these enzymes is of great interest. We developed an in vitro selection method that interrogates 10 11 dnA sequences for cleavage by active, dimeric ZFns. the method revealed hundreds of thousands of dnA sequences, some present in the human genome, that can be cleaved in vitro by two ZFns: ccr5-224 and VF2468, which target the endogenous human CCR5 and VEGFA genes, respectively. Analysis of identified sites in one cultured human cell line revealed ccr5-224-induced changes at nine off-target loci, though this remains to be tested in other relevant cell types. similarly, we observed 31 off-target sites cleaved by VF2468 in cultured human cells. our findings establish an energy compensation model of ZFn specificity in which excess binding energy contributes to off-target ZFn cleavage and suggest strategies for the improvement of future ZFn design.
Zinc-finger nucleases (ZFNs) are enzymes engineered to recognize and cleave desired target DNA sequences. A ZFN monomer consists of a zinc-finger DNA-binding domain fused with a nonspecific FokI restriction endonuclease cleavage domain 1 . As the FokI nuclease domain must dimerize and bridge two DNA half-sites to cleave DNA 2 , ZFNs are designed to recognize two unique sequences flanking a spacer sequence of variable length and to cleave only when bound as a dimer. ZFNs have been used for genome engineering in many organisms including mammals [3] [4] [5] [6] [7] [8] [9] by stimulating either nonhomologous end joining or homologous recombination. In addition to providing powerful research tools, ZFNs also have potential as gene therapy agents. Clinical trials have recently started with two ZFNs: one as part of an anti-HIV therapeutic approach (CCR5-224 clinical trials NCT00842634, NCT01044654 and NCT01252641) and the other to modify cells used as anticancer therapeutics (NCT01082926).
DNA cleavage specificity is a crucial feature of ZFNs. The imperfect specificity of some engineered zinc-fingers domains has been linked to cellular toxicity 10 , and therefore determining the specificities of ZFNs is of considerable interest. ELISA assays 11 , microarrays 12 , a bacterial one-hybrid system 13 , systematic evolution of ligands by exponential enrichment (SELEX) and its variants [14] [15] [16] , and Rosetta-based computational predictions 17 have all been used to characterize the DNA-binding specificity of monomeric zinc-finger domains in isolation. But the toxicity of ZFNs is believed to result from DNA cleavage rather than binding alone 18, 19 . As a result, information about the specificity of ZFNs to date has been based on the unproven assumptions that (i) dimeric ZFNs cleave DNA with the same sequence specificity with which isolated monomeric zinc-finger domains bind DNA; and (ii) the binding of one zincfinger domain does not influence the binding of the other zincfinger domain in a given ZFN. The DNA-binding specificities of monomeric zinc-finger domains have been used to predict potential off-target cleavage sites of dimeric ZFNs in genomes 6, 20, 21 , but to our knowledge no study to date has reported a method for determining the broad DNA cleavage specificity of active, dimeric ZFNs.
Here we present an in vitro selection method to broadly examine the DNA cleavage specificity of active ZFNs. We coupled our selection with high-throughput DNA sequencing to evaluate two obligate heterodimeric ZFNs, CCR5-224 (ref. 6) , currently in clinical trials, and VF2468 (ref. 4) , which targets the human VEGFA promoter, for their abilities to cleave each of 10 11 potential target sites. We identified 37 sites and 2,652 sites in the human genome that can be cleaved in vitro by the ZFNs CCR5-224 and VF2468, respectively, and hundreds of thousands of in vitro-cleavable sites for both ZFNs that are not present in the human genome. We examined 34 sites or 90 sites for evidence of ZFN-induced mutagenesis in cultured human K562 cells expressing the CCR5-224 or VF2468 respectively. Ten of the CCR5-224 sites and 32 of the VF2468 sites we tested had DNA sequence changes consistent with ZFN-mediated cleavage in human cells, although we anticipate that cleavage is likely to be dependent on cell type and ZFN concentration. One CCR5-224 off-target site lies in the promoter of the malignancy-associated BTBD10 gene.
Our results, which could not have been obtained by determining binding specificities of monomeric zinc-finger domains alone, indicate that excess DNA-binding energy results in increased off-target ZFN cleavage activity and suggest that ZFN specificity can be enhanced by designing ZFNs with decreased binding affinity, by lowering ZFN expression and by choosing target sites that differ by at least three base pairs from their closest sequence relatives in the genome.
results

In vitro selection for ZFn-mediated dnA cleavage
We prepared libraries of potential cleavage sites as double-stranded DNA using synthetic primers and PCR ( Supplementary Fig. 1 ). We ordered primers with each partially randomized position in the primer synthesized by incorporating a mixture containing 79% wild-type phosphoramidite and 21% of an equimolar mixture of all three other phosphoramidites. Library sequences therefore differed from canonical ZFN cleavage sites by 21% on average, distributed binomially. We used a blunt ligation strategy to create a 10 12 -member minicircle library. Using rolling-circle amplification, we both amplified and concatenated >10 11 members of this library into high-molecular-weight (>12-kilobase (kb)) DNA molecules. In theory, this library covers with at least tenfold excess all DNA sequences that are seven or fewer mutations from the wild-type target sequences.
We incubated the CCR5-224 or VF2468 DNA cleavage site library at a total cleavage site concentration of 14 nM with twofold dilutions, ranging from 0.5 nM to 4 nM, of crude in vitrotranslated CCR5-224 or VF2468, respectively ( Supplementary  Fig. 2 ). After digestion, we subjected the resulting DNA molecules ( Supplementary Fig. 3 ) to in vitro selection for DNA cleavage and subsequent paired-end high-throughput DNA sequencing. Briefly, three selection steps ( Fig. 1 and Supplementary Note 1) enabled the separation of sequences that were cleaved from those that were not cleaved. First, only sites that had been cleaved contained 5′ phosphates, which are necessary for the ligation of adapters required for sequencing. Second, after a PCR, gel purification enriched the smaller, cleaved library members. Finally, a computational filter applied after sequencing only counted sequences that have filled-in, complementary 5′ overhangs on both ends, the hallmark for cleavage of a target site concatemer ( Supplementary Table 1 , Supplementary Note 2 and Supplementary Protocols 1-9). We prepared 'preselection' library sequences for sequencing by cleaving the library at a PvuI restriction endonuclease recognition site adjacent to the library sequence and subjecting the digestion products to the same protocol as the ZFN-digested library sequences. High-throughput sequencing confirmed that the rolling-circleamplified, preselection library contained the expected distribution of mutations ( Supplementary Fig. 4 ).
off-target cleavage is dependent on ZFn concentration
As expected, each enzyme cleaved only a subset of library members. The preselection libraries for CCR5-224 and VF2468 had means of 4.56 and 3.45 mutations per complete target site (two half-sites), respectively, whereas 'postselection' libraries exposed to the highest concentrations of ZFN (4 nM CCR5-224 and 4 nM VF2468) during the in vitro selection had means of 2.79 and 1.53 mutations per target site, respectively ( Supplementary Fig. 4 ). We note that this selection strategy will most likely not recover all cleaved sequences owing to limitations in sequencing throughput.
As ZFN concentration decreased, both ZFNs exhibited less tolerance for off-target sequences. At the lowest concentrations (0.5 nM CCR5-224 and 0.5 nM VF2468), cleaved sites contained an average of 1.84 and 1.10 mutations, respectively. We placed a small subset of the identified sites in a new DNA context and incubated the constructs in vitro with 2 nM CCR5-224 or 1 nM VF2468 for 4 h at 37 °C ( Supplementary Fig. 5 ). We observed cleavage for all tested sites, and those sites emerging from the more stringent (low ZFN concentration) selections were cleaved more efficiently than those from the less stringent selections. All of the tested sequences contained several mutations, yet some were cleaved in vitro more efficiently than the designed target.
The DNA-cleavage specificity profile of the dimeric CCR5-224 ZFN ( Fig. 2a and Supplementary Fig. 6a,b ) was notably different than the DNA-binding specificity profiles of the CCR5-224 monomers previously determined by SELEX 6 Figure 1 | In vitro selection for ZFN-mediated cleavage. Preselection library members are concatemers (represented by arrows) of identical ZFN target sites lacking 5′ phosphates (P). L, left half-site; R, right half-site, S, spacer; and L′, S′ and R′ are sequences complementary to L, S and R, respectively. ZFN cleavage reveals a 5′ phosphate, which is required for ligation of sequencing adapters (red and blue). The only sequences that can be amplified by PCR using primers complementary to the red and blue adapters are sequences that have been cleaved twice and have adapters on both ends. DNA cleaved at adjacent sites is purified via gel electrophoresis and sequenced. A computational screening step after sequencing ensures that the filled-in spacer sequences (S and S′) are complementary and therefore from the same molecule.
exhibited tolerance for off-target base pairs in our cleavage selection that had not been predicted by the SELEX study. VF2468, which had not been previously characterized with respect to either DNA-binding or DNA-cleavage specificity, revealed two positions, (−)C5 and (+)A9, that exhibited limited sequence preference, suggesting that they were poorly recognized by the ZFNs (Fig. 2b and Supplementary Fig. 6c,d ). We note that 2 nM CCR5-224 and 1 nM VF2468 cleave with similar efficiencies in vitro ( Supplementary Fig. 2d ), and therefore we show these data together in Figure 2 .
compensation between half-sites affects dnA recognition
Our results revealed that ZFN substrates with mutations in one half-site are more likely to have additional mutations in nearby positions in the same half-site compared to the preselection library and are less likely to have additional mutations in the other halfsite. Although this effect was greatest when the most strongly specified base pairs were mutated ( Supplementary Fig. 7) , we observed this compensatory phenomenon for all specified half-site positions for both the CCR5 and VEGFA-targeting ZFNs ( Fig. 3 and Supplementary Fig. 8 ). For a minority of nucleotides in cleaved sites, such as VF2468 target site positions (+)G1, (-)G1, (-)A2 and (-)C3, mutation led to decreased tolerance of mutations in base pairs in the other half-site and also a slight decrease, rather than an increase, in mutational tolerance in the same half-site. When two of these mutations, (+)G1 and (-)G1, were included at the same time, mutational tolerance at all other positions decreased ( Supplementary Fig. 9 ). Thus, tolerance of mutations at one halfsite is influenced by DNA recognition at the other half-site.
This compensation model for ZFN site recognition applies not only to non-ideal half-sites but also to spacers with non-ideal lengths. In general, the ZFNs cleaved at characteristic locations in the spacers (Supplementary Fig. 10) , and preferentially cleaved 5-base-pair (bp) and 6-bp spacers over 4-bp and 7-bp spacers ( Supplementary Figs. 11 and 12) . However, cleaved sites with 5-bp or 6-bp spacers had greater sequence tolerance at the flanking half-sites than sites with 4-bp or 7-bp spacers ( Supplementary  Fig. 13 ). Therefore, spacer imperfections, similar to half-site mutations, lead to more stringent in vitro recognition of other regions of the DNA substrate.
ZFns can cleave many sequences with up to three mutations
We calculated enrichment factors for all sequences containing three or fewer mutations by dividing each sequence's frequency of occurrence in the postselection libraries by its frequency of occurrence in the preselection libraries. Among sequences enriched by cleavage (enrichment factor > 1), CCR5-224 could cleave all unique single-mutant sequences, 93% of all unique double-mutant sequences and half of all possible triple-mutant sequences ( Fig. 4a and Supplementary Table 2a ) at the highest enzyme concentration used. VF2468 could cleave 98% of all unique single-mutant sequences, half of all unique double-mutant sequences and 17% of all triple-mutant sequences ( Fig. 4b and Supplementary Table 2b ).
Because our approach assays active ZFN dimers, it revealed the complete sequences of ZFN sites that can be cleaved. Ignoring the sequence of the spacer, the selection revealed 37 sites in the human genome with 5-bp or 6-bp spacers that CCR5-224 can cleave in vitro ( Table 1 and Supplementary Table 3 ), and 2,652 sites in the human genome that VF2468 can cleave in vitro (Supplementary Data). Among the genomic sites that VF2468 cleaved in vitro, 1,428 sites had three or fewer mutations relative to the canonical target 
site (excluding the spacer sequence). Despite greater discrimination against single-, double-and triple-mutant sequences by VF2468 compared to CCR5-224 ( Fig. 4 and Supplementary Table 2) , the larger number of in vitro-cleavable VF2468 sites reflects the difference in the number of sites in the human genome that are three or fewer mutations away from the VF2468 target site (3,450 sites) versus those that are three or fewer mutations away from the CCR5-224 target site (8 sites) ( Supplementary Table 4 ).
identified sites are cleaved by ZFns in human cells
We tested whether CCR5-224 could cleave at sites identified by our selections in human cells by expressing CCR5-224 in K562 cells and examining 34 potential target sites in the human genome for evidence of ZFN-induced mutations using PCR and In sequences, lower-case letters indicate mutations compared to the target site. Sites marked with an 'X' were found in the corresponding in vitro selection dataset. Site sequences are listed as 5′-(+) half-site-spacer-(-) half-site -3′. Therefore, the (+) half-site is listed in the reverse sense from the way it is listed in the sequence profiles. K562 modification frequency is the frequency of observed sequences showing significant (P < 0.05) evidence of nonhomologous end-joining repair (Online Methods) in cells expressing active ZFN compared to cells expressing empty vector. Sites that did not show significant evidence of modifications are listed as not detected (ND), and K562 cell line modification frequency is blank for the three sites that were not analyzed owing to nonspecific PCR amplification from the genome. Additional information is available in supplementary tables 3 and 5. 100  90  80  70  60  50  40  30  20  10  0   100  90  80  70  60  50  40  30  20 Percentages of sequences with one, two or three mutations that are enriched for in vitro cleavage (enrichment factor >1) by CCR5-224 ZFN (a) and VF2468 ZFN (b). Enrichment factors were calculated for each sequence identified in the selection by dividing the observed frequency of that sequence in the postselection library by the frequency of that sequence in the preselection library.
high-throughput DNA sequencing. We defined sites with evidence of ZFN-mediated cleavage as those with insertion or deletion mutations (indels) characteristic of nonhomologous endjoining repair ( Supplementary Table 5 ) that were significantly enriched (P < 0.05) in cells expressing active CCR5-224 compared to control cells containing an empty vector. We obtained ~100,000 sequences for each site analyzed, which enabled us to detect that sites were modified at frequencies of at least ~1 in 10,000. Our analysis identified ten such sites: the intended target sequence in CCR5, a previously identified sequence in CCR2 and eight other off-target sequences ( Table 1 and Supplementary Tables 3  and 5) , one of which was in the promoter of the BTBD10 gene. The eight newly identified off-target sites were modified at frequencies of 1:300 to 1:5,300. We also expressed VF2468 in cultured K562 cells and performed the same analysis as above for 90 of the most highly cleaved sites identified by in vitro selection. Of the 90 VF2468 sites analyzed, 32 had indels consistent with ZFNmediated targeting in K562 cells ( Supplementary Table 6 ). We did not obtain site-specific PCR amplification products for three CCR5-224 sites and seven VF2468 sites, and therefore could not analyze the occurrence of nonhomologous end-joining at those loci. Taken together, these observations indicate that off-target sequences identified through the in vitro selection method include DNA sequences that can be cleaved by ZFNs in human cells.
discussion
Using the method presented here we identified hundreds of thousands of sequences that can be cleaved by two active, dimeric ZFNs, including many that are present and can be cut in the genome of human cells. One newly identified cleavage site for CCR5-224 is in the promoter of BTBD10. When downregulated, BTBD10 has been associated with malignancy 22 and with pancreatic beta-cell apoptosis 23 . When upregulated, BTBD10 has been shown to enhance neuronal cell growth 24 and pancreatic beta-cell proliferation through phosphorylation of Akt family proteins 23, 24 . This potentially important off-target cleavage site, as well as seven others we observed in cells, had not been identified in a recent study 6 that used in vitro monomer-binding data to predict potential CCR5-224 substrates. Although our selection results increased the number of known CCR5-224 off-target sites, the number of sequence reads obtained per selection in our study (approximately one million) is likely insufficient to cover all cleaved sequences in the postselection libraries. It is therefore possible that additional off-target cleavage sites for CCR5-224 and VF2468 could be identified in the human genome as sequencing capabilities improve. It is also possible that the datasets generated by this method could be used to develop computational models to predict additional ZFN cleavage sites in vitro and in cells.
We have previously shown that ZFNs that can cleave at sites in one cell line may not necessarily function in a different cell line 4 most likely because of local differences in chromatin structure. Therefore, it is likely that a different subset of the in vitro-cleavable off-target sites would be modified by CCR5-224 or VF2468 when expressed in different cell lines. Likewise, cell-line choice may influence purely cellular studies of endonuclease specificity, such as a recent study of homing endonuclease off-target cleavage that relied on adeno-associated virus integration into homing endonucleasecreated double-strand breaks in cells 25 . Whereas our in vitro method does not account for some features of cellular DNA, it provides general, cell type-independent information about endonuclease specificity and off-target sites that can inform subsequent studies performed in cell types of interest.
Although both ZFNs we analyzed had been engineered to a unique sequence in the human genome, both cleave several off-target sites in cells. This finding is particularly surprising for the four-finger CCR5-224 pair given that its theoretical specificity is 4,096-fold better than that of the three-finger VF2468 pair (CCR5-224 should recognize a 24-bp site that is 6 bp longer than the 18-bp VF2468 site). Examination of the CCR5-224 and VF2468 cleavage profiles and mutational tolerances of sequences with three or fewer mutations suggests different strategies may be required to engineer variants of these ZFNs with reduced off-target cleavage activities. The four-finger CCR5-224 showed a more diffuse range of positions with relaxed specificity and a higher tolerance of mutant sequences with three or fewer mutations than the three-finger VF2468 ZFN. For VF2468, re-optimization of only a subset of fingers may enable a substantial reduction in undesired cleavage events. For CCR5-224, in contrast, a more extensive reoptimization of many or all fingers may be required to eliminate off-target cleavage events. Analysis of more three-finger and four-finger ZFNs will be required to determine whether these patterns of off-target cleavage activities are a general property of these respective frameworks.
Not all four-and three-finger ZFNs will necessarily be as specific as the two ZFNs tested in this study. Both CCR5-224 and VF2468 had been engineered using methods designed to optimize the binding activity of the ZFNs. Previous work has shown that for both three-finger and four-finger ZFNs, the specific methodology used to engineer the ZFN pair can have a tremendous impact on the quality and specificity of nucleases 7, 13, 26, 27 . Therefore, it will be interesting and important to use a method such as the one described here to determine and compare the specificities of additional three-finger and four-finger ZFNs generated using various strategies.
Our findings have important implications for the design and application of ZFNs with increased specificity. Half or more of all potential substrates with one or two site mutations could be cleaved by ZFNs, suggesting that binding affinity between ZFN and DNA substrate is sufficiently high for cleavage to occur even with suboptimal molecular interactions at mutant positions. We also observed that ZFNs presented with sites that have mutations in one half-site exhibited higher mutational tolerance at other positions in the mutated half-site and lower tolerance at positions in the other half-site. These results suggest that to meet a minimum affinity threshold for cleavage, a shortage of binding energy from a half-site containing an off-target base pair must be energetically compensated by excess zinc finger:DNA binding energy in the other half-site, which demands increased sequence recognition stringency at the nonmutated half-site ( Supplementary Fig. 14) . Conversely, the relaxed stringency at other positions in mutated half-sites can be explained by the decreased contribution of that mutant half-site to overall ZFN binding energy.
This model also explains our observation that sites with suboptimal spacer lengths, which presumably were bound less favorably by ZFNs, were recognized with higher stringency than sites with optimal spacer lengths. In vitro spacer preferences do not necessarily reflect spacer preferences in cells 28, 29 , but our results suggest that the dimeric FokI cleavage domain can influence ZFN target-site recognition. Consistent with this model, differences in the frequency of off-target events in zebrafish of two ZFNs with identical zinc-finger domains but different FokI domain variants have been reported 20 .
Collectively, our findings suggest that (i) ZFN specificity can be increased by avoiding the design of ZFNs with excess DNA binding energy; (ii) off-target cleavage can be minimized by designing ZFNs to target sites that do not have similar sites in the genome within three mutations; and (iii) ZFNs should be used at the lowest concentrations necessary to cleave the target sequence to the desired extent. Although in this study we focused on ZFNs, our method should be applicable to all sequence-specific endonucleases that cleave DNA in vitro, including engineered homing endonucleases and engineered transcription activatorlike effector nucleases. This approach can provide important information when choosing target sites in genomes for sequencespecific endonucleases and when engineering these enzymes, especially for therapeutic applications.
methods
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemethods/.
